3 results
Primary objective *To determine Maximum Tolerated Dose (MTD) of TH-302 combined with chemoradiotherapy (23 x1.8 Gy in combination with Carboplatinum and Paclitaxel) in patients with distal esophageal or esophago-gastric junction adenocarcinoma, and…
The primary objective is to evaluate the effect of UDCA and ezetimibe on cholesterol elimination assessed as total faecal sterol concentration. Secondary objective is to assess the effect of UDCA and ezetimibe on plasma lipid profile/composition.
Given the limited effectiveness of available EGFR TKIs in patients with NSCLC with EGFR exon 20 insertion mutations, this subset patient population is routinely treated with chemotherapy, similar to patients with no driver mutations (ie, WT EGFR).…